JP5923509B2 - Ｃｄｋ阻害剤 - Google Patents

Ｃｄｋ阻害剤 Download PDF

Info

Publication number
JP5923509B2
JP5923509B2 JP2013535153A JP2013535153A JP5923509B2 JP 5923509 B2 JP5923509 B2 JP 5923509B2 JP 2013535153 A JP2013535153 A JP 2013535153A JP 2013535153 A JP2013535153 A JP 2013535153A JP 5923509 B2 JP5923509 B2 JP 5923509B2
Authority
JP
Japan
Prior art keywords
compound
formula
butyl
tert
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013535153A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013543845A (ja
JP2013543845A5 (https=
Inventor
フランシス、エックス．タバレス
ジェイ、シー．ストラム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
G1 Therapeutics Inc
Original Assignee
G1 Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46024778&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5923509(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by G1 Therapeutics Inc filed Critical G1 Therapeutics Inc
Publication of JP2013543845A publication Critical patent/JP2013543845A/ja
Publication of JP2013543845A5 publication Critical patent/JP2013543845A5/ja
Application granted granted Critical
Publication of JP5923509B2 publication Critical patent/JP5923509B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/499—Spiro-condensed pyrazines or piperazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
JP2013535153A 2010-10-25 2011-10-25 Ｃｄｋ阻害剤 Active JP5923509B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40649810P 2010-10-25 2010-10-25
US61/406,498 2010-10-25
PCT/US2011/057749 WO2012061156A1 (en) 2010-10-25 2011-10-25 Cdk inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016082206A Division JP6157680B2 (ja) 2010-10-25 2016-04-15 Ｃｄｋ阻害剤

Publications (3)

Publication Number Publication Date
JP2013543845A JP2013543845A (ja) 2013-12-09
JP2013543845A5 JP2013543845A5 (https=) 2014-12-18
JP5923509B2 true JP5923509B2 (ja) 2016-05-24

Family

ID=46024778

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2013535153A Active JP5923509B2 (ja) 2010-10-25 2011-10-25 Ｃｄｋ阻害剤
JP2016082206A Active JP6157680B2 (ja) 2010-10-25 2016-04-15 Ｃｄｋ阻害剤
JP2017110115A Active JP6389926B2 (ja) 2010-10-25 2017-06-02 Ｃｄｋ阻害剤
JP2018153563A Ceased JP2018193400A (ja) 2010-10-25 2018-08-17 Ｃｄｋ阻害剤

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2016082206A Active JP6157680B2 (ja) 2010-10-25 2016-04-15 Ｃｄｋ阻害剤
JP2017110115A Active JP6389926B2 (ja) 2010-10-25 2017-06-02 Ｃｄｋ阻害剤
JP2018153563A Ceased JP2018193400A (ja) 2010-10-25 2018-08-17 Ｃｄｋ阻害剤

Country Status (25)

Country Link
US (2) US8598186B2 (https=)
EP (6) EP2632467B1 (https=)
JP (4) JP5923509B2 (https=)
KR (4) KR102051881B1 (https=)
CN (5) CN106967074A (https=)
AU (5) AU2011323739B2 (https=)
BR (1) BR112013010018B1 (https=)
CA (2) CA2961937C (https=)
CY (1) CY1118004T1 (https=)
DK (1) DK2632467T3 (https=)
ES (1) ES2592515T3 (https=)
HK (2) HK1197067A1 (https=)
HR (1) HRP20161092T1 (https=)
HU (1) HUE030714T2 (https=)
IL (5) IL225940A0 (https=)
LT (1) LT2632467T (https=)
MX (4) MX338327B (https=)
PL (1) PL2632467T3 (https=)
PT (1) PT2632467T (https=)
RS (1) RS55135B1 (https=)
RU (1) RU2621674C2 (https=)
SG (2) SG10201508715YA (https=)
SI (1) SI2632467T1 (https=)
SM (1) SMT201600311B (https=)
WO (1) WO2012061156A1 (https=)

Families Citing this family (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
JP5465720B2 (ja) 2008-07-08 2014-04-09 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール
JP2012526850A (ja) 2009-05-13 2012-11-01 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル サイクリン依存性キナーゼ阻害剤及びその用法
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
WO2012068381A2 (en) 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
CA2868966C (en) 2012-03-29 2021-01-26 Francis Xavier Tavares Lactam kinase inhibitors
CA2870019C (en) * 2012-04-26 2020-08-18 Francis Xavier Tavares Synthesis of lactams
RS58514B1 (sr) 2012-06-13 2019-04-30 Incyte Holdings Corp Supstituisana triciklična jedinjenja kao inhibitori fgfr
ME03557B (me) 2013-03-15 2020-07-20 G1 Therapeutics Inc Privremena zaštiтa normalnih ćelija током hemoterapije
US20140274896A1 (en) * 2013-03-15 2014-09-18 G1 Therapeutics, Inc. Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
CA2906157C (en) * 2013-03-15 2022-05-17 G1 Therapeutics, Inc. Highly active anti-neoplastic and anti-proliferative agents
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
WO2015161288A1 (en) * 2014-04-17 2015-10-22 G1 Therapeutics, Inc. Tricyclic lactams for use as anti-neoplastic and anti-proliferative agents
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016126889A1 (en) * 2015-02-03 2016-08-11 G1 Therapeutics, Inc. Cdk4/6 inhibitor dosage formulations for the protection of hematopoietic stem and progenitor cells during chemotherapy
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2018005863A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
WO2018005533A1 (en) * 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Antiproliferative pyrimidine-based compounds
WO2018005865A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Synthesis of n-(heteroaryl)-pyrrolo[3,2-d]pyrimidin-2-amines
RU2019102647A (ru) * 2016-07-01 2020-08-03 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
BR112019003722A2 (pt) 2016-08-23 2019-05-28 Eisai R&D Man Co Ltd terapias de combinação para o tratamento de carcinoma hepatocelular
US10849903B2 (en) 2016-10-20 2020-12-01 Pfizer Inc. Anti-proliferative agents for treating PAH
US11865176B2 (en) 2016-11-08 2024-01-09 Dana-Farber Cancer Institute, Inc. Compositions and methods of modulating anti-tumor immunity
EP3505519B1 (en) * 2016-11-11 2022-01-05 Shanghai Haiyan Pharmaceutical Technology Co., Ltd. Pyridinamine-substituted heterotricyclo compounds, preparation thereof, and use in medicines
KR20190092478A (ko) 2016-12-05 2019-08-07 쥐원 쎄라퓨틱스, 인크. 화학요법 레지멘 동안의 면역 반응의 보존
MX2019008158A (es) 2017-01-06 2019-12-09 G1 Therapeutics Inc Terapia de combinacion para el tratamiento del cancer.
US11395821B2 (en) 2017-01-30 2022-07-26 G1 Therapeutics, Inc. Treatment of EGFR-driven cancer with fewer side effects
EP3585389A4 (en) 2017-02-22 2020-12-23 G1 Therapeutics, Inc. EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS
MX2019010981A (es) 2017-03-16 2020-09-07 Eisai R&D Man Co Ltd Terapias de combinacion para el tratamiento de cancer de mama.
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019006393A1 (en) 2017-06-29 2019-01-03 G1 Therapeutics, Inc. Morphic forms of git38 and methods of manufacture thereof
CN107383019B (zh) * 2017-07-28 2019-10-15 江苏艾凡生物医药有限公司 吡唑并[4,3-h]喹唑啉类化合物及其用途
CN109985241B (zh) * 2017-12-29 2024-10-18 广州威溶特医药科技有限公司 Cdk抑制剂和溶瘤病毒在制备抗肿瘤药物的应用
EP3738084A4 (en) 2018-01-08 2021-11-17 G1 Therapeutics, Inc. SUPERIOR G1T38 DOSING SCHEMES
TWI877770B (zh) 2018-02-27 2025-03-21 美商英塞特公司 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶
HRP20241288T1 (hr) 2018-05-04 2024-12-06 Incyte Corporation Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
WO2020010197A1 (en) 2018-07-05 2020-01-09 Incyte Corporation Fused pyrazine derivatives as a2a / a2b inhibitors
AU2019325685B2 (en) 2018-08-24 2025-07-24 Pharmacosmos Holding A/S Improved synthesis of 1,4-diazaspiro(5.5)undecan-3-one
EP3849537B1 (en) 2018-09-10 2024-10-23 Mirati Therapeutics, Inc. Combination therapies
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
CN113271977A (zh) * 2018-11-09 2021-08-17 G1治疗公司 使用艾日布林和选择性cdk4/6抑制剂组合治疗癌症的治疗方案
US20220040324A1 (en) 2018-12-21 2022-02-10 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
CN111377924A (zh) * 2018-12-29 2020-07-07 武汉光谷通用名药物研究院有限公司 新型cdk4抑制剂及其用途
CN111377935B (zh) * 2018-12-29 2021-06-29 武汉光谷通用名药物研究院有限公司 选择性cdk4/6抑制剂及其应用
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
PH12021551976A1 (en) 2019-02-15 2022-07-04 Incyte Corp Cyclin-dependent kinase 2 biomarkers and uses thereof
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2020205560A1 (en) 2019-03-29 2020-10-08 Incyte Corporation Sulfonylamide compounds as cdk2 inhibitors
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
WO2020223469A1 (en) 2019-05-01 2020-11-05 Incyte Corporation N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
TW202114684A (zh) 2019-06-18 2021-04-16 美商G1治療公司 增強癌症病患之抗腫瘤免疫之方法
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
KR20220044527A (ko) 2019-08-01 2022-04-08 인사이트 코포레이션 Ido 억제제의 투여 요법
CA3150681A1 (en) 2019-08-14 2021-02-18 Incyte Corporation Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US11851426B2 (en) 2019-10-11 2023-12-26 Incyte Corporation Bicyclic amines as CDK2 inhibitors
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP7832891B2 (ja) 2019-12-04 2026-03-18 インサイト・コーポレイション Ｆｇｆｒ阻害剤の誘導体
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021178779A1 (en) 2020-03-06 2021-09-10 Incyte Corporation Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
JP2021167301A (ja) 2020-04-08 2021-10-21 ファイザー・インク Ｃｄｋ２阻害剤に対する腫瘍適応を抑制するためのｃｄｋ４／６およびｃｄｋ２阻害剤による同時処置
AU2021254794A1 (en) 2020-04-16 2022-12-15 Incyte Corporation Fused tricyclic KRAS inhibitors
US11739102B2 (en) 2020-05-13 2023-08-29 Incyte Corporation Fused pyrimidine compounds as KRAS inhibitors
KR20230012547A (ko) 2020-05-19 2023-01-26 쥐원 쎄라퓨틱스, 인크. 의학적 장애의 치료를 위한 시클린-의존성 키나제 억제 화합물
EP4165046B1 (en) 2020-06-11 2025-09-17 Lunella Biotech, Inc. Selective cdk4/6 inhibitor cancer therapeutics
EP4164653A4 (en) * 2020-06-15 2024-06-19 G1 Therapeutics, Inc. MORPHIC FORMS OF TRILACICLIB AND METHODS OF PREPARING THE SAME
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
US11999752B2 (en) 2020-08-28 2024-06-04 Incyte Corporation Vinyl imidazole compounds as inhibitors of KRAS
US11767320B2 (en) 2020-10-02 2023-09-26 Incyte Corporation Bicyclic dione compounds as inhibitors of KRAS
US20230374028A1 (en) * 2020-10-08 2023-11-23 Teva Pharmaceuticals International Gmbh Solid state forms of trilaciclib and of trilaciclib salts
WO2022155941A1 (en) 2021-01-25 2022-07-28 Qilu Regor Therapeutics Inc. Cdk2 inhibitors
WO2022206888A1 (en) 2021-03-31 2022-10-06 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
MX2024000357A (es) 2021-07-07 2024-02-12 Incyte Corp Compuestos triciclicos como inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras).
WO2023287896A1 (en) 2021-07-14 2023-01-19 Incyte Corporation Tricyclic compounds as inhibitors of kras
CA3227191A1 (en) 2021-07-26 2023-02-02 Celcuity Inc. 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer
CN113788837B (zh) * 2021-08-02 2022-08-26 深圳湾实验室坪山生物医药研发转化中心 Trilaciclib的合成方法
US12441742B2 (en) 2021-08-31 2025-10-14 Incyte Corporation Naphthyridine compounds as inhibitors of KRAS
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
CA3234375A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
CA3235146A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
MX2024006113A (es) 2021-11-22 2024-07-29 Incyte Corp Terapia de combinación que comprende un inhibidor del receptor del factor de crecimiento de fibroblastos (fgfr) y un inhibidor del sarcoma de rata de kirsten (kras).
WO2023102184A1 (en) 2021-12-03 2023-06-08 Incyte Corporation Bicyclic amine compounds as cdk12 inhibitors
US12084453B2 (en) 2021-12-10 2024-09-10 Incyte Corporation Bicyclic amines as CDK12 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors
EP4452982A1 (en) 2021-12-22 2024-10-30 Incyte Corporation Salts and solid forms of an fgfr inhibitor and processes of preparing thereof
WO2023116884A1 (en) 2021-12-24 2023-06-29 Qilu Regor Therapeutics Inc. Cdk2 inhibitors and use thereof
WO2023168686A1 (en) 2022-03-11 2023-09-14 Qilu Regor Therapeutics Inc. Substituted cyclopentanes as cdk2 inhibitors
US20250136610A1 (en) 2022-02-28 2025-05-01 Teva Pharmaceuticals International Gmbh Crystalline forms of trilaciclib and trilaciclib salts
JP2025512710A (ja) 2022-03-07 2025-04-22 インサイト・コーポレイション Ｃｄｋ２阻害剤の固体形態、塩、ならびに調製プロセス
AR129675A1 (es) 2022-06-22 2024-09-18 Incyte Corp Inhibidores de cdk12 de aminas biciclicas
US20240101557A1 (en) 2022-07-11 2024-03-28 Incyte Corporation Fused tricyclic compounds as inhibitors of kras g12v mutants
CN115536663A (zh) * 2022-10-11 2022-12-30 杭州科巢生物科技有限公司 一种曲拉西利中间体及其制备与应用
EP4626866A1 (en) * 2022-11-28 2025-10-08 Assia Chemical Industries Ltd. Novel trilaciclib intermediates, method of preparation and use thereof
CR20250500A (es) 2023-04-18 2026-01-12 Incyte Corp Inhibidores de kras de 2-azabiciclo [2.2.1] heptano
US20240390340A1 (en) 2023-04-18 2024-11-28 Incyte Corporation Pyrrolidine kras inhibitors
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
IT202300010182A1 (it) 2023-05-19 2024-11-19 Olon Spa Forma solvata di trilaciclib di-cloridrato.
IT202300010824A1 (it) * 2023-05-29 2024-11-29 Olon Spa Forma solvata di trilaciclib di-cloridrato.
WO2024246713A1 (en) * 2023-05-29 2024-12-05 Fresenius Kabi Oncology Ltd A process for the preparation of cdk inhibiting pyrrolopyrimidine compounds
WO2024254245A1 (en) 2023-06-09 2024-12-12 Incyte Corporation Bicyclic amines as cdk2 inhibitors
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
CN117069663B (zh) * 2023-08-31 2023-12-26 四川维亚本苑生物科技有限公司 一种瑞博西尼中间体v的合成方法及瑞博西尼的合成方法
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025096738A1 (en) 2023-11-01 2025-05-08 Incyte Corporation Kras inhibitors
US20250195536A1 (en) 2023-12-13 2025-06-19 Incyte Corporation Bicyclooctane kras inhibitors
WO2025134057A1 (en) 2023-12-20 2025-06-26 Assia Chemical Industries Ltd. Solid state forms of trilaciclib citrate salt
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
US20260053814A1 (en) 2024-08-21 2026-02-26 Celcuity Inc. Treatment regimens for gedatolisib in hormonally-driven disorders
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
US20260069605A1 (en) 2024-09-11 2026-03-12 Incyte Corporation Kras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
US20260098044A1 (en) 2024-10-04 2026-04-09 Incyte Corporation Tricyclic heteroaryl compounds as inhibitors of tyk2 and/or jak1

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0738717A1 (en) * 1990-10-09 1996-10-23 Neurogen Corporation Certain substituted pyrimidines as intermediates for production of cycloalkyl and azacycloalkyl pyrrolopyrimidines
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
EA012926B1 (ru) * 2001-12-20 2010-02-26 Оси Фармасьютикалз, Инк. Пирролопиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение
MXPA04005939A (es) 2002-01-22 2005-01-25 Warner Lambert Co 2-(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas.
US20050176796A1 (en) * 2002-02-19 2005-08-11 D'alessio Roberto Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents
MXPA05007503A (es) 2003-01-17 2005-09-21 Warner Lambert Co Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular.
BR122019010200B8 (pt) * 2003-05-22 2021-07-27 Nerviano Medical Science S R L compostos de pirazol-quinazolina, seus sais, produtos ou kits e composições farmacêuticas
ES2297502T3 (es) 2003-10-23 2008-05-01 F. Hoffmann-La Roche Ag Derivados de triaza-espiropiperidinas para uso como inhibidores de glyt-1 en el tratamiento de trastornos neurologicos y neuropsiquiatricos.
GB0327380D0 (en) * 2003-11-25 2003-12-31 Cyclacel Ltd Method
ITMI20040874A1 (it) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori Derivati indolici ed azaindolici con azione antitumorale
EP1779848A1 (en) 2005-10-28 2007-05-02 Nikem Research S.R.L. V-ATPase inhibitors for the treatment of inflammatory and autoimmune diseases
TWI398252B (zh) * 2006-05-26 2013-06-11 諾華公司 吡咯并嘧啶化合物及其用途
MX2009006613A (es) * 2006-12-21 2009-07-02 Nerviano Medical Sciences Srl Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa.
CA2690748A1 (en) 2007-06-25 2008-12-31 Neurogen Corporation Piperazinyl oxoalkyl tetrahydro-beta-carbolines and related analogues
EA201001030A1 (ru) * 2007-12-19 2011-02-28 Амген Инк. Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
ES2522346T3 (es) * 2008-08-22 2014-11-14 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de CDK
JP2012504646A (ja) 2008-10-01 2012-02-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 選択的サイクリン依存性キナーゼ４／６阻害剤を用いた化学療法化合物に対する造血系の防護
CN102231983A (zh) 2008-10-01 2011-11-02 北卡罗来纳大学查珀尔希尔分校 使用选择性细胞周期蛋白依赖性激酶4/6抑制剂对抗电离辐射的造血防护
JP2012526850A (ja) 2009-05-13 2012-11-01 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル サイクリン依存性キナーゼ阻害剤及びその用法
US9040519B2 (en) 2010-02-18 2015-05-26 Medivation Technologies, Inc. Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use
CA2868966C (en) * 2012-03-29 2021-01-26 Francis Xavier Tavares Lactam kinase inhibitors

Also Published As

Publication number Publication date
IL252108A0 (en) 2017-07-31
MX385616B (es) 2025-03-18
PT2632467T (pt) 2016-08-29
MX367795B (es) 2019-09-06
EP2955183A1 (en) 2015-12-16
KR20190135556A (ko) 2019-12-06
CN106008533B (zh) 2018-01-23
KR101929593B1 (ko) 2018-12-14
AU2016204879B2 (en) 2018-02-01
EP3118203A1 (en) 2017-01-18
EP3981770A1 (en) 2022-04-13
RU2013123790A (ru) 2014-12-10
CN103429243B (zh) 2016-06-08
AU2020203037A1 (en) 2020-05-28
CA2961937C (en) 2018-09-25
KR20180135086A (ko) 2018-12-19
BR112013010018B1 (pt) 2020-11-10
US8598197B2 (en) 2013-12-03
SMT201600311B (it) 2016-11-10
MX2013004681A (es) 2013-10-17
HRP20161092T1 (hr) 2016-10-21
IL237581B (en) 2018-11-29
HK1197067A1 (en) 2015-01-02
IL237581A0 (en) 2015-04-30
SG189525A1 (en) 2013-05-31
AU2011323739A1 (en) 2013-05-02
PL2632467T3 (pl) 2016-12-30
US20130237533A1 (en) 2013-09-12
HUE030714T2 (en) 2017-05-29
JP2017186357A (ja) 2017-10-12
AU2011323739B2 (en) 2016-05-12
EP2632467A4 (en) 2014-03-26
CA2815084C (en) 2017-05-09
EP3118203B1 (en) 2018-10-24
IL237582A0 (en) 2015-04-30
CN103429243A (zh) 2013-12-04
LT2632467T (lt) 2016-09-12
CN103936745B (zh) 2017-04-12
RS55135B1 (sr) 2016-12-30
IL271977A (en) 2020-02-27
CN106967074A (zh) 2017-07-21
SI2632467T1 (sl) 2016-10-28
MX379532B (es) 2025-03-10
CY1118004T1 (el) 2017-05-17
AU2018202991B2 (en) 2020-02-13
MX338327B (es) 2016-04-12
KR102186969B1 (ko) 2020-12-04
RU2621674C2 (ru) 2017-06-07
AU2016204879A1 (en) 2016-07-28
IL252108B (en) 2020-02-27
HK1254345B (en) 2020-04-09
JP2016183161A (ja) 2016-10-20
ES2592515T3 (es) 2016-11-30
EP2632467B1 (en) 2016-06-22
CN103936745A (zh) 2014-07-23
EP3567042A1 (en) 2019-11-13
MX2020005498A (es) 2021-08-26
JP2013543845A (ja) 2013-12-09
EP3567042B1 (en) 2021-07-07
BR112013010018A2 (pt) 2016-08-02
AU2018202991A1 (en) 2018-05-17
WO2012061156A1 (en) 2012-05-10
MX2019010602A (es) 2019-10-17
KR20140003427A (ko) 2014-01-09
KR20200137048A (ko) 2020-12-08
SG10201508715YA (en) 2015-11-27
US8598186B2 (en) 2013-12-03
EP3381920A1 (en) 2018-10-03
EP2632467A1 (en) 2013-09-04
CN106008533A (zh) 2016-10-12
JP6157680B2 (ja) 2017-07-05
CA2961937A1 (en) 2012-05-10
JP6389926B2 (ja) 2018-09-12
DK2632467T3 (en) 2016-08-15
JP2018193400A (ja) 2018-12-06
IL225940A0 (en) 2013-06-27
CN104045654A (zh) 2014-09-17
EP3381920B1 (en) 2019-03-27
US20130237544A1 (en) 2013-09-12
CA2815084A1 (en) 2012-05-10
AU2020203035B2 (en) 2021-09-16
AU2020203037B2 (en) 2021-09-09
AU2020203035A1 (en) 2020-05-28
KR102051881B1 (ko) 2019-12-04
IL271977B (en) 2021-04-29

Similar Documents

Publication Publication Date Title
JP6389926B2 (ja) Ｃｄｋ阻害剤
US20240109906A1 (en) Cdk inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141027

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141027

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150709

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150710

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151013

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160226

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160418

R150 Certificate of patent or registration of utility model

Ref document number: 5923509

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350